American College of Cardiology

EVOLUT LOW RISK: Self-Expanding TAVR vs. Surgery at Six Years in Low-Risk Patients With AS

Six years after undergoing either surgery or TAVR with a CoreValve, Evolut R or Evolut PRO, low-risk patients with aortic stenosis (AS) experienced no significant differences in terms of all-cause ...